- Home
- TRDA
as 11-24-2025 3:34pm EST
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 350.5M | IPO Year: | 2021 |
| Target Price: | $24.50 | AVG Volume (30 days): | 293.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.93 - $21.79 | Next Earning Date: | 11-06-2025 |
| Revenue: | $61,520,000 | Revenue Growth: | -71.42% |
| Revenue Growth (this year): | -81.01% | Revenue Growth (next year): | -13.42% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Nov 21 '25 | Sell | $9.98 | 8,910 | $88,931.60 | 110,026 | |
| BAKER BROS. ADVISORS LP | TRDA | 10% Owner | Nov 20 '25 | Buy | $9.07 | 28,867 | $261,846.12 | 4,691,392 | |
| PARMAR KUSH | TRDA | Director, 10% Owner | Nov 14 '25 | Sell | $8.80 | 200,000 | $1,760,000.00 | 2,963,066 | |
| 5AM Ventures V, L.P. | TRDA | 10% Owner | Nov 14 '25 | Sell | $8.80 | 200,000 | $1,760,000.00 | 2,963,066 | |
| BAKER BROS. ADVISORS LP | TRDA | 10% Owner | Nov 12 '25 | Buy | $7.84 | 100,736 | $781,637.97 | 4,691,392 | |
| BAKER BROS. ADVISORS LP | TRDA | 10% Owner | Nov 11 '25 | Buy | $7.47 | 46,434 | $348,193.01 | 4,691,392 | |
| BAKER BROS. ADVISORS LP | TRDA | 10% Owner | Nov 10 '25 | Buy | $7.22 | 30,874 | $222,755.70 | 4,691,392 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
19 days ago
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
GlobeNewswire
6 months ago
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire
6 months ago
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Clinical Trials Arena
6 months ago
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
GlobeNewswire
6 months ago
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Simply Wall St.
6 months ago
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
Zacks
7 months ago
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.